EFFECT OF TAUROURSODEOXYCHOLIC ACID ON SERUM LIVER-ENZYME AND SERUM-LIPID LEVELS IN PATIENTS WITH CHRONIC ACTIVE HEPATITIS

被引：4
作者：
ANGELICO, M
DELVECCHIO, C
NISTRI, A
机构：
[1] UNIV CATANIA,CATANIA,ITALY
[2] UNIV ROMA LA SAPIENZA,ROME,ITALY
来源：
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL | 1995年 / 56卷 / 06期
关键词：
D O I：
10.1016/0011-393X(95)85055-4
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Tauroursodeoxycholic acid (TUDCA) is a new natural bile acid amidate being investigated as a gallstone-dissolving agent in humans. We report herein the results of a multicenter, cooperative study that involved 12 hospitals throughout Italy, aimed at evaluating the effects of long-term oral administration of TUDCA (500 mg/d for 3 months) on serum liver enzymes, total bilirubin, and serum lipid levels in patients with biopsy-proven chronic active hepatitis due to hepatitis C virus (HCV) or hepatitis B virus (HBV) infection. The study population included 134 anti-HCV-positive and 28 hepatitis B surface antigenpositive patients. TUDCA was well tolerated and safe and was associated with a significant (P < 0.001) decrease in all serum liver enzyme levels. Aspartate aminotransferase, alanine aminotransferase, and gamma-glutamyltransferase levels decreased by a mean of 29.7 +/- 14.5%, 24.1 +/- 15.9%, and 26.6 +/- 19.9%, respectively, after 1 month of therapy and by an additional 5% to 10% by the end of 3 months of therapy. A slight improvement in total bilirubin levels was also observed. In addition, TUDCA caused a slight, but significant, improvement in serum lipid profiles (decreased total cholesterol [P < 0.001] and triglycerides [P < 0.05] and increased high-density lipoprotein cholesterol [NS]). These favorable changes were similar in HCV and HBV hepatitis and were independent of age, sex, body weight, and alcohol consumption. These results indicate that TUDCA may have a place in the treatment of patients with chronic hepatitis, a possibility that needs to be verified by means of long-term, prospective, placebocontrolled, double-blind studies.
引用
收藏
页码：626 / 634
页数：9
相关论文
共 20 条
  • [1] Angelico, Della Guardia, Baiocchi, Et al., Cholesterol crystal onset and growth kinetics in gallbladder bile after administration of tauroursodeoxycholic and ursodeoxycholic acid in man, J Hepatol, 18, (1993)
  • [2] Cantafora, DiBiase, Angelico, Alvaro, Study of biologically relevant physical-chemical properties of bile salts by reverse-phase liquid chromatography, Chromatographia, 24, pp. 277-281, (1987)
  • [3] Igimi, Carey, pH-solubility relations of chenodeoxycholic and ursodeoxycholic acids: Physical-chemical basis for dissimilar solution and membrane phenomena, J Lipid Res, 21, pp. 72-90, (1980)
  • [4] Hofmann, Mysels, Bile acid solubility and precipitation in vitro and in vivo: The role of conjugation, pH, and Ca<sup>2+</sup> ions, J Lipid Res, 33, pp. 617-626, (1992)
  • [5] Magnuson, Lillemoe, Zarkin, Pitt, Patients with uncomplicated cholelithiasis acidify bile normally, Dig Dis Sci, 37, pp. 1517-1522, (1992)
  • [6] Aldini, Roda, Simoni, Et al., Uptake of bile acids by perfused rat liver: Evidence for a structure-activity relationship, Hepatology, 10, pp. 840-845, (1989)
  • [7] Kitani, Kanai, Ohta, Sato, Differing transport maximal values for taurine-conjugated bile salts in rats and hamsters, Am J Physiol, 251, pp. G852-G858, (1990)
  • [8] Scholmerich, Becher, Schmidt, Et al., Influence of hydroxylation and conjugation of bile salts on their membrane damaging properties: Studies on isolated hepatocytes and lipid membrane vesicles, Hepatology, 4, pp. 661-666, (1984)
  • [9] Heuman, Pandak, Hylemon, Vlahcevic, Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts: In vitro studies in rat hepatocytes and human erythrocytes, Hepatology, 14, pp. 920-926, (1991)
  • [10] Poupon, Balkau, Eschwege, Poupon, UDCA-PBC Study Group. A multicenter controlled trial of ursodiol for the treatment of primary biliary cirrhosis, NEJM, 324, pp. 1548-1554, (1991)
12